Impairment due to a decline in the recoverability of fixed assets
First written in FY2019. 8 of 15 entries say "Materialised", first in FY2019. Latest entry: FY2026.
Jtec moved to the "Worse" side of this theme in 2022, 1 year after the typical company in this theme (2021).
The whole theme swung hardest in 2020: 51 of 96 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「The group may need to recognize impairment losses on property, plant and equipment and goodwill, which could affect its operating results and financial position.」
The company explicitly expands the previous risk concerning the decline in recoverability of fixed assets to include the impairment risk relating to goodwill arising from the acquisition of 電子科学株式会社. No impairment loss was recognized during the fiscal year. - FY2026-H1MitigatedAnnual report
「(Material impairment losses on property, plant and equipment) Not applicable.」
No material impairment loss on fixed assets was recognized for the six-month period. The situation improved from the ¥21 thousand impairment loss recognized in the Life Science and Equipment Development Business in the same period of the previous year. - FY2025-H1MitigatedAnnual report
「In the Life Science and Equipment Development Business segment, the company recognized an impairment loss of ¥21 thousand due to a decline in profitability.」
The company recognized an impairment loss of ¥21 thousand on fixed assets for the business, down from ¥442 thousand in the same period of the previous year. - FY2024MaterialisedAnnual report
「During the fiscal year, the group recognized impairment losses on the following asset group: Ibaraki City, Osaka Prefecture For the Life Science and Equipment Development Business Research and development equipment Machinery and equipment ¥23.414 million Tools, furniture and fixtures ¥442 thousand」
The company recognized total impairment losses of ¥23.857 million on research and development equipment for the Life Science and Equipment Development Business. This was higher than the ¥2.803 million recognized in the previous fiscal year. - FY2024-Q3MaterialisedAnnual report
「In the Life Science and Equipment Development Business segment, the company recognized an impairment loss of ¥1.837 million due to a decline in profitability.」
An impairment loss of ¥1.837 million on fixed assets due to a decline in profitability in the Life Science and Equipment Development Business was actually recognized. - FY2024-Q1MaterialisedAnnual report
「In the Life Science and Equipment Development Business segment, the company recognized an impairment loss of ¥442 thousand due to a decline in profitability.」
The impairment risk arising from a decline in the recoverability of fixed assets materialized as an impairment loss of ¥442 thousand in the Life Science and Equipment Development Business. - FY2023-Q3MaterialisedAnnual report
「In the Life Science and Equipment Development Business segment, the company recognized an impairment loss of ¥2.803 million due to a decline in profitability.」
An impairment loss of ¥2.803 million due to a decline in profitability in the Life Science and Equipment Development Business was actually recognized. - FY2023-Q2MaterialisedAnnual report
「In the Life Science and Equipment Development Business segment, the company recognized an impairment loss of ¥2.549 million due to a decline in profitability.」
An impairment loss of ¥2.549 million due to a decline in profitability in the Life Science and Equipment Development Business was actually recognized for the six-month period ended 30 September. - FY2023-Q1MaterialisedAnnual report
「In the Life Science and Equipment Development Business segment, the company recognized an impairment loss of ¥2.4 million due to a decline in profitability.」
The impairment risk arising from a decline in the recoverability of fixed assets materialized as an impairment loss of ¥2.4 million in the Life Science and Equipment Development Business. - FY2022RestatedAnnual report
「For the research and development equipment of the Life Science and Equipment Development Business, the company considered the business environment and future outlook, including the fact that research and development currently precedes other activities due to the nature of the business. As a result of examining recoverability, it reduced the carrying amount to the recoverable amount and recognized the resulting reduction of ¥578 thousand as an impairment loss under extraordinary losses.」
The annual results also confirm that an impairment loss of ¥578 thousand was recognized on research and development equipment for the Life Science and Equipment Development Business. - FY2022-Q3MaterialisedAnnual report
「In the Life Science and Equipment Development Business segment, the company recognized an impairment loss of ¥578 thousand due to a decline in profitability.」
The impairment risk arising from a decline in the recoverability of fixed assets materialized as an impairment loss of ¥578 thousand in the Life Science and Equipment Development Business. - FY2020RestatedAnnual report
「If the estimated future cash flows from the relevant assets decline and their recoverability deteriorates, the company may need to recognize impairment losses on fixed assets, which could affect its operating results and financial position.」
The company continues to describe the decline in recoverability of fixed assets and the related impairment risk. No impairment loss was recognized during the fiscal year. - FY2019MaterialisedAnnual report
「If the estimated future cash flows from the relevant assets decline and their recoverability deteriorates, the company may need to recognize impairment losses on fixed assets, which could affect its operating results and financial position.」
The company generally describes the risk of impairment of fixed assets. During the fiscal year, it recognized an impairment loss of ¥1 million on research and development equipment for the life science and equipment development business.